Evidence map›Paper›PMID 39872403›Full record

ReviewOrthopedic research and reviews2025

β-Caryophyllene and Statins in Bone Fracture Healing - A Narrative Review.

Hilik Marom, Mansoor A Khan, Nissim Darvish, Paul Tornetta Iii, Amal Khoury, Yoram A Weil, Nathan W M Skelley, Daniel C Allison, Sahar Meiron, Tami Ehrmann Barr

Abstract readReview
In one paragraph

Review in Orthopedic research and reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hilik Marom *R&D, OrthoTreat Ltd, Tel Aviv-Jaffa, Israel.
Mansoor A Khan *R&D, OrthoTreat Ltd, Tel Aviv-Jaffa, Israel.
Nissim Darvish *Corporate Office, OrthoTreat Ltd, Tel Aviv-Jaffa, Israel.
Paul Tornetta Iii *Department of Orthopaedic Surgery and Orthopaedic Trauma, Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston, MA, USA.
Amal Khoury *Division of Orthopaedic Surgery, Orthopaedic, and Reconstructive Trauma Surgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Yoram A Weil *Department of Orthopaedics, Hadassah Hebrew University Hospital, Jerusalem, Israel.
Nathan W M Skelley *Department of Orthopaedics, Sanford Health, Sioux Falls, SD, USA.
Daniel C Allison *Department of Orthopaedic Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sahar Meiron *Corporate Office, OrthoTreat Ltd, Tel Aviv-Jaffa, Israel.ORCID 0009-0009-8807-0161
Tami Ehrmann Barr *R&D, OrthoTreat Ltd, Tel Aviv-Jaffa, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone fractures are a leading cause of morbidity and healthcare expenditure globally. The complex healing process involves inflammation, cartilage formation, mineralization, and bone remodeling. Current treatments like immobilization, surgery, and bone grafting, though effective, pose significant challenges, such as prolonged recovery and high costs. Emerging therapies such as biological agents, pharmacological treatments, and physical stimulation techniques are also associated with high costs, side effects, and practical applicability limitations. There is a critical need for alternative therapies that are cost-effective, safe, and easy to use. Recent studies suggest the potential of β-caryophyllene (BCP) and statins in promoting bone healing. BCP, a naturally occurring anti-inflammatory and antioxidant compound found in essential oils, enhances osteoblast activity and inhibits osteoclastogenesis. Statins, known for their cholesterol-lowering effects, also promote bone formation and reduce bone resorption through multiple biochemical pathways. Both BCP and statins have shown promising results in preclinical studies, enhancing bone density and promoting fracture healing. This review explores the individual and potential synergistic effects of BCP and statins on bone fracture healing. It highlights the complementary mechanisms of these agents: BCP's anti-inflammatory and osteogenic properties and statins' ability to inhibit osteoclast activity and promote angiogenesis. Combining BCP and statins could offer a multifaceted approach to enhance fracture healing, reduce complications, and improve patient outcomes. While individual effects are supported preclinically, further studies investigating synergies, formulations, and clinical translation are needed to develop this promising novel therapeutic approach for improving fracture repair outcomes.

Indexed as

bone regenerationfracture repairosteoblastosteogenesispiezoelectric effect

Identifiers

PMID39872403
PMCPMC11771162

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.